Cancer News and Research

Latest Cancer News and Research

Breast-conserving surgery carries high reoperation risk

Women who undergo breast-conserving surgery for breast cancer may be at an increased risk for reoperation, research suggests.

20 Jul 2012

Sanquin, Baxter enter manufacturing services agreement for plasma therapies

Baxter International Inc. today announced that it has entered into a manufacturing services agreement with Stichting Sanquin Bloedvoorziening (Sanquin Blood Supply Foundation) in the Netherlands that will provide Baxter up to 1.6 million liters of incremental plasma fractionation capacity annually to support global growth of plasma-derived treatments.

From Baxter International Inc. 20 Jul 2012

Keystone Symposia on Molecular and Cellular Biology receives Gates Foundation grant

Keystone Symposia on Molecular and Cellular Biology is pleased to announce that it has received a fourth grant from the Bill & Melinda Gates Foundation to promote discoveries that will solve urgent global health problems via support of infectious disease conferences in the "Keystone Symposia Global Health Series."

20 Jul 2012

Moderate alcohol consumption may reduce risk of kidney cancer

A majority of previous epidemiologic studies have shown that moderate drinking is associated with a lower risk of kidney cancer, which may affect about 1% of the general population. In published prospective cohort studies, the risk for such cancer among moderate drinkers is usually about 25% less than the risk seen among non-drinkers.

20 Jul 2012

SGC, Life Technologies to generate first-ever master set of epigenetic recombinant antibodies

Life Technologies Corporation today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.

20 Jul 2012

Bristol-Myers Squibb reports results from brivanib plus sorafenib phase III trial on HCC

Bristol-Myers Squibb Company today reported the result of the phase III BRISK-FL clinical trial of the investigational agent brivanib versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

20 Jul 2012

Researchers identify six genes with driving mutations in melanoma

It's been a burning question in melanoma research: Tumor cells are full of ultraviolet (UV)-induced genetic damage caused by sunlight exposure, but which mutations drive this cancer? None have been conclusively tied to melanoma. The sheer abundance of these passenger mutations has obscured the search for genetic driver mutations that actually matter in melanoma development and progression.

20 Jul 2012

Study helps explain why leukemia occurs more frequently as people age

Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows.

20 Jul 2012

Cepheid second quarter 2012 revenues increase 21% to $81.0 million

Cepheid today reported revenues for the second quarter of 2012 of $81.0 million, representing growth of 21% from $67.0 million for the second quarter of 2011.

20 Jul 2012

Teva contributes $2.5M to The Franklin Institute for development of neuroscience exhibit

The Franklin Institute has received a $2.5 million contribution from leading global pharmaceutical company Teva Pharmaceuticals to develop a signature innovative exhibit at the museum exploring neuroscience and the human brain, entitled Your Brain. This contribution brings The Franklin Institute's Inspire Science fundraising campaign total to $65 million.

20 Jul 2012

Cubist second quarter total net revenues increase 30% to $230.6M

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2012.

20 Jul 2012

GUMC, MedStar GUH launch Huntington Disease Care, Education and Research Center

Georgetown University Medical Center in collaboration with MedStar Georgetown University Hospital announce the launch of the Huntington Disease Care, Education and Research Center.

20 Jul 2012

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces it has signed a binding term sheet with Vestiq for the commercialization rights in the United States of Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults.

20 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

Longer looks: Physicians and assisted suicide; Avoid getting sick in July

Peggy Sutherland was ready to die. The morphine oozing from a pump in her spine was no match for the pain of lung cancer, which had evaded treatment and invaded her ribs. … Sutherland, 68, decided to use Oregon's "Death With Dignity Act," which allows terminally-ill residents to end their lives after a 15-day requisite waiting period by self-administering a lethal prescription drug. ... But not all doctors are on board with the law.

20 Jul 2012

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics' and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer.

20 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Patients, partners affected by colorectal cancer course

Partners of individuals with colorectal cancer, as well as the patients themselves, are at risk for psychologic morbidity according to the type of treatment given, show Portuguese study results.

19 Jul 2012

NeoGenomics second quarter 2012 revenue increases 49% to $15.6 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2012.

19 Jul 2012

Researchers discover potential drug targets that might reduce ventilator-induced lung inflammation

When hospital patients need assistance breathing and are placed on a mechanical ventilator for days at a time, their lungs react to the pressure generated by the ventilator with an out-of-control immune response that can lead to excessive inflammation, new research suggests.

19 Jul 2012